The Role of Pro-angiogenic Immune Cells in Human Pregnancies

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01177020

Enrollment

300

Registered

2010-08-06

Start date

2010-08-31

Completion date

2011-12-31

Last updated

2010-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Growth Retardation, Preeclampsia

Brief summary

Identification of the presence of proangiogenic immune cells in normal human placentas may enable predication of some pregnancy disorders.

Interventions

OTHERBiological specimen

Biological specimen taken from placenta

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

* Placentas that have been delivered in the Medical Center

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
To find the angiogenic potential of proangiogenic immune cells derived from human placentas.	Two years

Countries

Israel

Contacts

Primary ContactElad Mei-Dan, MD

eladmei@yahoo.com972-4-6304248

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026